Inform and Raise Awareness
On this page
Inform and Raise Awareness
Using this website
Go back to parent page
Our services
By informing and spreading awareness, we ensure that the Horizon Europe programme becomes known and readily accessible to all potential applicants, irrespective of sector or discipline.

How to find your way on the NCP Flanders website

This website is an important source of information and communication channel with our stakeholders. There is a news section, event calendar and a document and video library which can be searched with key words of your choice.

For each Horizon Europe and Horizon 2020 programme part a dedicated page offers the latest information on these programmes. Cross-programme subjects are summarised in info sheets.

Flemish stakeholders can create a myHORIZON account to receive regular updates in their mail box. Examples of projects with Flemish beneficiaries are showcased via the Inspire page and testimonies throughout our website.

Outside the Horizon framework programmes many other EU funding sources on research and innovation exist which can be consulted via the EU other funding page. The EU Funding Overview is an exhaustive overview of EU funding programmes and agencies.

Please take a look around and in case you would have any question do not hesitate to get in touch with us!

 

Testimonial

image of BEAT-AF - Ground-Breaking Electroporation-based intervention for Atrial Fibrillation treatment

BEAT-AF - Ground-Breaking Electroporation-based intervention for Atrial Fibrillation treatment

The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.